E2 ModerateModerate confidencePEM ?Cross-SectionalPeer-reviewedMachine draft
Patients with Fibromyalgia and Chronic Fatigue Syndrome show increased hsCRP compared to healthy controls.
Groven, Nina, Fors, Egil A, Reitan, Solveig Klæbo · Brain, behavior, and immunity · 2019 · DOI
Quick Summary
This study measured inflammation markers in the blood of people with ME/CFS and fibromyalgia, compared to healthy people. Both patient groups had higher levels of a marker called hsCRP (a sign of inflammation) than healthy controls. The two conditions showed similar inflammation levels, suggesting they may share some biological similarities.
Why It Matters
This study provides objective biological evidence that ME/CFS involves measurable immune activation, supporting the view that it is not purely psychological. Finding that both ME/CFS and fibromyalgia share elevated inflammation suggests these conditions may have overlapping pathophysiological mechanisms, which could guide future research into shared treatment approaches.
Observed Findings
- Both CFS and FM groups had significantly higher hsCRP levels than healthy controls (p < .001)
- No significant difference in hsCRP levels between CFS and FM patient groups
- hsCRP levels were independently associated with BMI but not with age or smoking status
- Findings remained significant after adjusting for age, smoking, and BMI
Inferred Conclusions
- Measurable inflammation appears to be present in both ME/CFS and fibromyalgia
- CES and FM may share common inflammatory pathophysiology despite their clinical differences
- hsCRP alone cannot be used as a biomarker to differentiate between ME/CFS and fibromyalgia
Remaining Questions
- Does elevated hsCRP change over the disease course, and does it correlate with symptom severity or progression?
- What upstream factors drive hsCRP elevation in ME/CFS—what is the source of the inflammatory signal?
- Do subgroups within ME/CFS exist that show different inflammatory profiles, and could hsCRP identify them?
- Would longitudinal follow-up reveal whether hsCRP normalization occurs with treatment or recovery?
What This Study Does Not Prove
This study does not prove that elevated hsCRP causes ME/CFS or fibromyalgia—it only shows an association. It also does not establish whether hsCRP elevation is primary to disease pathology or secondary to other factors, and cannot distinguish between the two conditions based on inflammation levels alone. The cross-sectional design prevents determination of causality or whether hsCRP changes over disease course.
Tags
Symptom:Fatigue
Biomarker:CytokinesBlood Biomarker
Method Flag:Weak Case DefinitionExploratory Only